Hims & Hers vs ShedRx (2026): prices, structure, verdict

On tirzepatide, only ShedRx↗ has a rankable figure: $289 a month all-in; Hims & Hers↗ routes tirzepatide through brand channels without a single compounded cash price — its cost depends on coverage or the manufacturer programs (Zepbound vials $299–$449; Wegovy $349).

Updated 2026-08-10 · figures captured 2026-08-09 · how we verify

On semaglutide, only ShedRx has a rankable figure: $249 a month all-in; Hims & Hers routes semaglutide through brand channels without a single compounded cash price — its cost depends on coverage or the manufacturer programs (Zepbound vials $299–$449; Wegovy $349).

§ Side by side

§ Each record, read aloud

The two records, condensed

Hims & Hers: the record, condensed

Hims & Hers routes tirzepatide through brand product — no single compounded cash figure exists to rank. The reference prices live one layer down: Zepbound (LillyDirect↗), $299–$449 a month cash, or whatever your insurance turns those numbers into.

On semaglutide, Hims & Hers is a brand channel rather than a priced product: it prescribes the FDA-approved medication, and what you pay depends on coverage or the manufacturer cash programs (Wegovy (NovoCare↗) at $199–$349).

Operationally at Hims & Hers: shipping included; commitment plan recurs; cancellation plan recurs until cancelled; pharmacy named (brand fulfillment; compounded program closed to new patients); states: 50 states; evidence no public price, captured 2026-08-05. The full record with source and archive links: the Hims & Hers page · visit Hims & Hers ↗

ShedRx: the record, condensed

ShedRx’s tirzepatide program bills $289 a month once every mandatory fee is counted, measured at the 10 mg maintenance basis. The structure is tiered: the advertised entry point is $199, but the maintenance figure — the one a full year is actually billed at — is $289. That $90 gap between the ad and the anniversary is the single most important line in this record.

Nothing recurs on top: no membership, no platform fee, no “provider access” line. The $289 is the whole subscription, which makes ShedRx unusually easy to compare and unusually easy to leave.

To place the number: #5 of 17 verified programs, with the floor $74/month below at NexLife↗ ($215); the approved-product yardstick (Zepbound (LillyDirect)) sits at $449, so the compounded case here is worth $160 a month. A year at this figure: $3,468 monthly-billed.

Start with the load-bearing figure: $249 a month, all-in, is what ShedRx charges for semaglutide at the 2.4 mg basis. The structure is tiered: the advertised entry point is $175, but the maintenance figure — the one a full year is actually billed at — is $249. That $74 gap between the ad and the anniversary is the single most important line in this record.

There is no membership line. $249 is the billed total — consultation and clinical review are inside it, and no platform fee recurs beside it, which removes the most common way advertised GLP-1 prices understate billed ones.

Context for that figure: it ranks #13 of 20 in the verified semaglutide index — $116/month above the floor (Oak Longevity, $133) — and sits $100 under the brand benchmark (Wegovy (NovoCare), $349 at maintenance). Annualized, a monthly-billed year here runs $2,988.

Operationally at ShedRx: shipping included; commitment none month-to-month; cancellation 72-hour notice before the next billing cycle; pharmacy not publicly named — ask in writing before paying; states: not published; evidence source-verified, captured 2026-08-05. The full record with source and archive links: the ShedRx page · visit ShedRx ↗

§ Structure vs structure

Everything besides the price

Coverage: Hims & Hers publishes “50 states”; ShedRx publishes “not published” — for anything short of an explicit 50-state claim, intake is the final word.

Pharmacy transparency splits them: Hims & Hers names its network (brand fulfillment; compounded program closed to new patients); ShedRx does not, which shifts the burden of verification onto your intake questions.

Exit terms: Hims & Hers — plan recurs; plan recurs until cancelled. ShedRx — none month-to-month; 72-hour notice before the next billing cycle.

Evidence: Hims & Hers no public price (captured 2026-08-05); ShedRx source-verified (2026-08-05).

The pattern worth internalizing: in this market, structural honesty and price honesty travel together. Programs that publish pharmacies and state lists tend to publish real maintenance prices; programs that hide one usually hide the other.

§ If you move

Switching between Hims & Hers and ShedRx

Prescriptions do not transfer like phone numbers: moving in either direction means completing the destination’s intake and having its prescriber write a new patient-specific prescription. The mechanics that prevent a bad month: confirm the destination serves your state and quotes your current dose in writing before cancelling anything; time the first new shipment to overlap the last old one rather than gap it; cancel the origin per its published terms (Hims & Hers: plan recurs until cancelled; ShedRx: 72-hour notice before the next billing cycle) and screenshot the confirmation; and never leave a prepaid balance stranded — which is the standing argument for prepaying only after a program has already earned a few monthly cycles.

§ Verdict by situation

Which one, for whom

§ More pairings